PWRM looks to develope new ways to Discover Disease- Brought to you by PennyTo Buck.com

July 16, 2010 - PRLog -- ARNA- Shares of Arena Pharmaceuticals /quotes/comstock/15*!arna/quotes/nls/arna (ARNA 4.48, +0.56, +14.28%) rallied 19% to $4.68 early Friday, the day after an advisory panel of the U.S. Food and Drug Administration voted not to recommend the approval of rival Vivus Inc.'s /quotes/comstock/15*!vvus/quotes/nls/vvus (VVUS 5.13, -6.98, -57.64%) diet drug Qnexa due to safety concerns. While the agency is not bound to the decisions of its panels, it generally follows them. ARNA diet drug lorcaserin, which is also awaiting FDA approval, is considered by many experts to have fewer safety issues than Qnexa. Meanwhile, shares of Orexigen Therapeutics /quotes/comstock/15*!orex/quotes/nls/orex (OREX 4.50, -0.50, -10.00%) , whose diet drug Contrave is also up for approval, tumbled 12% to $4.40. Many industry experts believe that while Contrave is safer than Qnexa, its safety profile may not be as strong as that of lorcaserin.

ARNA, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company also discovers small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its clinical development programs include lorcaserin that has completed Phase III clinical trials for the treatment of weight management; APD791, an anti-thrombotic drug candidate, which completed Phase Ia and Phase Ib clinical trials; APD597 that is in Phase I clinical trials for the treatment of type II diabetes; APD916, which has completed preclinical development for the treatment of narcolepsy and cataplexy; and APD811, a preclinical drug candidate for the treatment of pulmonary arterial hypertension.


a development stage company, engages in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, amyotrophic lateral sclerosis (ALS), Alzheimer?s disease, and Parkinson?s disease. Its product candidates include BC-SeraPro, a blood serum protein breast cancer test for the diagnosis of breast cancer and to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects.

PWRM continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS (Lou Gehrig’s disease), Alzheimer’s, Parkinson’s diseases, breast cancer, and drug resistance.

PWRM’s NuroPro Blood Test is diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease.

For more information on this company check website http://www.power3medical.com/